{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T20:30:14Z","timestamp":1648931414399},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2003,12,1]],"date-time":"2003-12-01T00:00:00Z","timestamp":1070236800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Gastro"],"published-print":{"date-parts":[[2003,12]]},"DOI":"10.1007\/s11938-003-0051-4","type":"journal-article","created":{"date-parts":[[2007,6,3]],"date-time":"2007-06-03T15:13:20Z","timestamp":1180883600000},"page":"493-498","source":"Crossref","is-referenced-by-count":7,"title":["Management of primary biliary cirrhosis"],"prefix":"10.1007","volume":"6","author":[{"given":"Cynthia","family":"Levy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith D.","family":"Lindor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"51_CR1","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0016-5085(94)94899-2","volume":"106","author":"R Jazrawi","year":"1994","unstructured":"Jazrawi R, Caestecker J, Goggin P, et al.: Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid. Gastroenterology 1994, 106:134\u2013142.","journal-title":"Gastroenterology"},{"key":"51_CR2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/hep.510300121","volume":"30","author":"K Yamazaki","year":"1999","unstructured":"Yamazaki K, Suzuki K, Nakamura A, et al.: Ursodeoxycholic acid inhibits eosinophil degranulation in patients with primary biliary cirrhosis. Hepatology 1999, 30:71\u201378.","journal-title":"Hepatology"},{"key":"51_CR3","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/hep.1840110104","volume":"11","author":"Y Calmus","year":"1990","unstructured":"Calmus Y, Gane P, Rouger P, et al.: Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology 1990, 11:12\u201315.","journal-title":"Hepatology"},{"key":"51_CR4","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1046\/j.1440-1746.2002.02672.x","volume":"17","author":"M Neuman","year":"2002","unstructured":"Neuman M, Angulo P, Malkiewicz I, et al.: Tumor necrosis factor-alpha and transforming growth factorbeta reflect severity of liver damage in primary biliary cirrhosis. J Gastroenterol Hepatol 2002, 17:196\u2013202.","journal-title":"J Gastroenterol Hepatol"},{"key":"51_CR5","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S0140-6736(87)91610-2","volume":"1","author":"R Poupon","year":"1987","unstructured":"Poupon R, Chretien Y, Poupon R, et al.: Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis. Lancet 1987, 1:834\u2013836.","journal-title":"Lancet"},{"key":"51_CR6","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1056\/NEJM199105303242204","volume":"324","author":"R Poupon","year":"1991","unstructured":"Poupon R, Balkau B, Eschwege E, et al.: A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med 1991, 324:1548\u20131554.","journal-title":"N Engl J Med"},{"key":"51_CR7","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/hep.1840190512","volume":"19","author":"E Heathcote","year":"1994","unstructured":"Heathcote E, Cauch-Dudek K, Walker V, et al.: The canadian multicenter double-blind randomized contolled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994, 19:1149\u20131156.","journal-title":"Hepatology"},{"key":"51_CR8","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/0016-5085(94)90021-3","volume":"106","author":"K Lindor","year":"1994","unstructured":"Lindor K, Rolland Dickson E, Baldus W, et al.: Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994, 106:1284\u20131290.","journal-title":"Gastroenterology"},{"key":"51_CR9","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0016-5085(97)70183-5","volume":"113","author":"R Poupon","year":"1997","unstructured":"Poupon R, Lindor K, Cauch-Dudek K, et al.: Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997, 113:884\u2013890.","journal-title":"Gastroenterology"},{"key":"51_CR10","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0140-6736(98)11293-X","volume":"354","author":"J Goulis","year":"1999","unstructured":"Goulis J, Leandro G, Burroughs A: Randomised controlled trials of ursodeoxycholic acid therapy for primary biliary cirrhosis: a meta-analyis. Lancet 1999, 354:1053\u20131060.","journal-title":"Lancet"},{"key":"51_CR11","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(05)72401-6","volume":"355","author":"K Lindor","year":"2000","unstructured":"Lindor K, Poupon R, Poupon R, et al.: Ursodeoxycholic acid for primary biliary cirrhosis. Lancet 2000, 355:657\u2013658.","journal-title":"Lancet"},{"key":"51_CR12","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0168-8278(00)80232-9","volume":"32","author":"R Poupon","year":"2000","unstructured":"Poupon R: Ursodeoxycholic acid for primary biliary cirrhosis: lessons from the past-issues for the future. J Hepatol 2000, 32:685\u2013688.","journal-title":"J Hepatol"},{"key":"51_CR13","first-page":"759","volume":"22","author":"B Combes","year":"1995","unstructured":"Combes B, Carithers R, Maddrey W, et al.: A randomized, double-blind, placebo controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995, 22:759\u2013766.","journal-title":"Hepatology"},{"key":"51_CR14","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3109\/00365529709000190","volume":"32","author":"L Erickson","year":"1997","unstructured":"Erickson L, Olsson R, Glauman H, et al.: Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multi-centre, double-blind, randomized controlled study. Scand J Gastroenterol 1997, 32:179\u2013186.","journal-title":"Scand J Gastroenterol"},{"key":"51_CR15","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.4065\/72.12.1137","volume":"72","author":"K Lindor","year":"1997","unstructured":"Lindor K, Jorgensen R, Therneau T, et al.: Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis. Mayo Clin Proc 1997, 72:1137\u20131140.","journal-title":"Mayo Clin Proc"},{"key":"51_CR16","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/hep.510290301","volume":"29","author":"P Angulo","year":"1999","unstructured":"Angulo P, Batts K, Therneau T, et al.: Long term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology 1999, 29:644\u2013647.","journal-title":"Hepatology"},{"key":"51_CR17","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1053\/jhep.2000.20240","volume":"32","author":"C Corpechot","year":"2000","unstructured":"Corpechot C, Carrat F, Bonnand A, et al.: The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 2000, 32:1196\u20131199.","journal-title":"Hepatology"},{"key":"51_CR18","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0168-8278(00)80216-0","volume":"32","author":"A Pares","year":"2000","unstructured":"Pares A, Caballeria L, Rodes J, et al.: Long term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. J Hepatol 2000, 32:561\u2013566.","journal-title":"J Hepatol"},{"key":"51_CR19","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1478-3231.1999.tb00020.x","volume":"19","author":"P Angulo","year":"1999","unstructured":"Angulo P, Lindor K, Therneau T, et al.: Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. Liver 1999, 19:115\u2013121.","journal-title":"Liver"},{"key":"51_CR20","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/hep.510290140","volume":"29","author":"A Bonnand","year":"1999","unstructured":"Bonnand A, Heathcote E, Lindor K, et al.: Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis. Hepatology 1999, 29:39\u201343.","journal-title":"Hepatology"},{"key":"51_CR21","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S0168-8278(99)80136-6","volume":"30","author":"P Angulo","year":"1999","unstructured":"Angulo P, Rolland Dickson E, Therneau T, et al.: Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. J Hepatol 1999, 30:830\u2013835.","journal-title":"J Hepatol"},{"key":"51_CR22","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/00042737-199906000-00007","volume":"11","author":"E Jones","year":"1999","unstructured":"Jones E, Bergasa N: The pathogenesis and treatment of pruritus and fatigue in patients with PBC. Eur J Gastroenterol Hepatol 1999, 11:623\u2013631.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"51_CR23","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/0016-5085(92)90102-5","volume":"102","author":"N Bergasa","year":"1992","unstructured":"Bergasa N, Talbot T, Alling D, et al.: A controlled trial of naloxone infusions for the pruritus of cholestasis. Gastroenterology 1992, 102:544\u2013549.","journal-title":"Gastroenterology"},{"key":"51_CR24","doi-asserted-by":"crossref","first-page":"161","DOI":"10.7326\/0003-4819-123-3-199508010-00001","volume":"123","author":"N Bergasa","year":"1995","unstructured":"Bergasa N, Alling D, Talbot T, et al.: Effects of naloxone infusions in patients with the pruritus of cholestasis: a double-blind randomised controlled trial. Ann Intern Med 1995, 123:161\u2013167.","journal-title":"Ann Intern Med"},{"key":"51_CR25","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/gast.1997.v113.pm9322521","volume":"113","author":"F Wolfhagen","year":"1997","unstructured":"Wolfhagen F, Sternieri E, Hop W, et al.: Oral naltrexone for cholestatic pruritus\u2014a double-blind, placebo-controlled study. Gastroenterology 1997, 113:1264\u20131269.","journal-title":"Gastroenterology"},{"key":"51_CR26","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/hep.510270307","volume":"27","author":"N Bergasa","year":"1998","unstructured":"Bergasa N, Schmitt J, Talbot T, et al.: Open label trial of oral nalmefene therapy for the pruritus of cholestasis. Hepatology 1998, 27:679\u2013684.","journal-title":"Hepatology"},{"key":"51_CR27","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0304-3959(94)00145-5","volume":"61","author":"H Schworer","year":"1995","unstructured":"Schworer H, Hartmann H, Ramadori G: Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondansetron. Pain 1995, 61:33\u201337.","journal-title":"Pain"},{"key":"51_CR28","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S0168-8278(01)00144-1","volume":"35","author":"K Menon","year":"2001","unstructured":"Menon K, Angulo P, Weston S, et al.: Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. J Hepatol 2001, 35:316\u2013323. Well-conducted study evaluating the prevalence of osteoporosis in a large cohort of patients with PBC. It determined that those with more advanced liver disease have a faster rate of bone loss. Other predictors of increased risk of bone disease were older age and lower body mass index (<24).","journal-title":"J Hepatol"},{"key":"51_CR29","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/jama.288.1.58","volume":"288","author":"S Hulley","year":"2002","unstructured":"Hulley S, Furberg C, Barrett-Connor E, et al.: Noncardiovascular disease outcomes during 6.8 years of hormone therapy (HERS II). JAMA 2002, 288:58\u201366.","journal-title":"JAMA"},{"key":"51_CR30","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0168-8278(00)80118-X","volume":"33","author":"K Lindor","year":"2000","unstructured":"Lindor K, Jorgensen R, Tiegs R, et al.: Etidronate for osteoporosis in primary biliary cirrhosis: a randomized trial. J Hepatol 2000, 33:878\u2013882.","journal-title":"J Hepatol"},{"key":"51_CR31","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1359\/jbmr.2000.15.3.515","volume":"15","author":"M Shiraki","year":"2000","unstructured":"Shiraki M, Shiraki Y, Aoki C, et al.: Vitamin K2 effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. J Bone Miner Res 2000, 15:515\u2013521.","journal-title":"J Bone Miner Res"},{"key":"51_CR32","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1111\/j.1572-0241.2001.04134.x","volume":"96","author":"J Phillips","year":"2001","unstructured":"Phillips J, Angulo P, Petterson T, et al.: Fat-soluble vitamin levels in patients with primary biliary cirrhosis. Am J Gastroenterol 2001, 96:2745\u20132750.","journal-title":"Am J Gastroenterol"},{"key":"51_CR33","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/hep.510290116","volume":"29","author":"T Pasha","year":"1999","unstructured":"Pasha T, Heathcote E, Gabriel S, et al.: Cost-effectiveness of ursodeoxycholic acid therapy in primary biliary cirrhosis. Hepatology 1999, 29:21\u201326.","journal-title":"Hepatology"},{"key":"51_CR34","unstructured":"Drug Topics Red Book. Montvale, NJ: Medical Economics; 2002."},{"key":"51_CR35","first-page":"253A","volume":"34","author":"SC Cauduro","year":"2001","unstructured":"Cauduro SC, Wiesner RH, Brandhagen DJ, et al.: Long term results of patients undergoing liver transplantation for primary biliary cirrhosis at a single center. Hepatology 2001, 34:253A.","journal-title":"Hepatology"},{"key":"51_CR36","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/lt.500050419","volume":"5","author":"E Heathcote","year":"1999","unstructured":"Heathcote E, Stone J, Cauch-Dudek K, et al.: Effect of pretransplantation ursodeoxycholic acid therapy on the outcome of liver transplantation in patients with primary biliary cirrhosis. Liver Transplant Surg 1999, 5:269\u2013274.","journal-title":"Liver Transplant Surg"}],"container-title":["Current Treatment Options in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-003-0051-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11938-003-0051-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-003-0051-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T20:56:59Z","timestamp":1559422619000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11938-003-0051-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,12]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2003,12]]}},"alternative-id":["51"],"URL":"https:\/\/doi.org\/10.1007\/s11938-003-0051-4","relation":{},"ISSN":["1092-8472","1534-309X"],"issn-type":[{"value":"1092-8472","type":"print"},{"value":"1534-309X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,12]]}}}